Respiratory pathogens: Assessing resistance patterns in Europe and the potential role of grepafloxacin as treatment of patients with infections caused by these organisms

Journal of Antimicrobial Chemotherapy

Volumn 45, Issue TOPIC T2, 2000, Pages 1-8

  Felmingham, David ^a  

^a GR Micro Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AMPICILLIN; AZITHROMYCIN; BETA LACTAMASE; CHLORAMPHENICOL; CIPROFLOXACIN; CLARITHROMYCIN; COTRIMOXAZOLE; DOXYCYCLINE; GREPAFLOXACIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT;

ANTIBIOTIC SENSITIVITY; ARTICLE; CHLAMYDOPHILA PNEUMONIAE; EUROPE; FRANCE; HAEMOPHILUS INFLUENZAE; HUMAN; ITALY; KLEBSIELLA PNEUMONIAE; LEGIONELLA PNEUMOPHILA; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MORAXELLA CATARRHALIS; MYCOPLASMA PNEUMONIA; OTITIS MEDIA; PREVALENCE; RESPIRATORY TRACT INFECTION; SINUSITIS; SPAIN; STREPTOCOCCUS PNEUMONIAE;

EID: 0034057321     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/45.suppl_2.1     Document Type: Article

References (20)

1. The World Health Report. (1997). Conquering Suffering, Enriching Humanity. World Health Organization, Geneva.
2. Mandell, L. A. (1995). Community-acquired pneumonia: etiology, epidemiology and treatment. Chest 108, 35S-42S.
3. Ball, P. (1995). Epidemiology and treatment of chronic bronchitis and its exacerbations. Chest 108, 43S-52S.
4. Goldstein, F., Bryskier, A., Appelbaum, P. C., Bauernfeind, A., Jacobs, M., Schito, G. C. et al. (1998). The etiology of respiratory tract infections and the antimicrobial activity of fluoroquinolones and other oral antibacterial agents against respiratory pathogens. Clinical Microbiology and Infection 4, Suppl. 2, S8-18.
5. Felmingham, D. (1995). Antibiotic resistance: do we need new therapeutic approaches? Chest 108, 70S-8S.
6. Felmingham, D. & Grüneberg, R. N. (1996). A multicentre collaborative study of the antimicrobial susceptibility of community-acquired, lower respiratory tract pathogens 1992-1993. The Alexander Project. Journal of Antimicrobial Chemotherapy 38, Suppl. A 1-57.
7. Felmingham, D. & Washington, J. (1999). Trends in the antimicrobial susceptibility of bacterial respiratory tract pathogens - findings of the Alexander Project 1992-1996. Journal of Chemotherapy 11, Suppl. 1, 5-21.
8. Baquero, F., Barrett, J. F., Courvalin, P., Morrissey, I., Piddock, L. & Novick, W. J. (1998). Epidemiology and mechanisms of resistance among respiratory tract pathogens. Clinical Microbiology and Infection 4, Suppl. 2, S19-26.
9. Felmingham, D., Grüneberg, R. N. and the Alexander Project Group. (2000). The Alexander Project 1996-1997: latest susceptibility data from this international study of bacterial pathogens from community-acquired lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 45, 191-203.
10. Leclerq, R. & Courvalin, P. (1993). Mechanisms of resistance to macrolides and functionally related antibiotics. In Macrolides, (Bryskier, A. J., Butzler, J.-P., Neu, H. C. & Tulkens, P. M., Eds), pp. 125-41. Blackwell, Paris.
11. Clairoux, N., Picard, M., Brochu, A., Rousseau, N., Gourde, P., Beauchamp, D. et al. (1992). Molecular basis of the non-β-lactamase-mediated resistance to β-lactam antibiotics in strains of Haemophilus influenzae isolated in Canada. Antimicrobial Agents and Chemotherapy 36, 1504-13.
12. Catlin, B. W. (1990). Branhamella catarrhalis: an organism gaining respect as a pathogen. Clinical Microbiology Reviews 3, 292-320.
13. Jorgensen, J. H., Doern, G. V., Maher, L. A., Howell, A. & Redding, J. S. (1990). Antimicrobial resistance among respiratory isolates of Haemophilus influenzas, Moraxella catarrhalis and Streptococcus pneumoniae in the United States. Antimicrobial Agents and Chemotherapy 34, 2075-80.
14. Geddes, A. M. (1997). Grepafloxacin - focus on respiratory infections. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 1-4.
15. Imada, T., Miyazaki, S., Nishida, M., Yamaguchi, K. & Goto, S. (1992). In vitro and in vivo antibacterial activities of a new quinolone, OPC-17116. Antimicrobial Agents and Chemotherapy 36, 573-9.
16. Efthymiopoulos, C. (1997). Pharmacokinetics of grepafloxacin. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 35-43.
17. Perry, S. F., Pontré, M., Jupp, J., Moult, A. & Grüneberg, R. N. (1998). In vitro activity of grepafloxacin against bacteria associated with community-acquired respiratory infection: a multi-centre European study. Clinical Infectious Diseases 27, 957 (Abstract 196)
18. Kinghorn-Perry, S. F., Pontré, M., Jupp, J., Moult, A. & Grüneberg, R. N. (1999). In vitro activity of grepafloxacin against clinical isolates obtained from laboratories in the European Union. Clinical Microbiology and Infection 5, Suppl. 3, 145 (Abstract 227).
19. National Committee for Clinical Laboratory Standards. (1997). Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically - Fourth Edition: Approved Standard M7-A4. NCCLS, Wayne, PA.
20. Ridgway, G. L., Salman, H., Robbins, M. J., Dencer, C. & Felmingham, D. (1997). The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. Journal of Antimicrobial Chemotherapy 40, Suppl. A, 31-4.